This meta-analysis was performed to evaluate the relationships between the monocyte chemoattractant protein-1 (MCP-1) −2518A>G (rs1024611 A>G) polymorphism and its serum levels, and the risk of cerebral infarction. The PubMed, CISCOM, CINAHL, Web of Science, Google Scholar, EBSCO, Cochrane Library, and CBM databases were searched for relevant articles published before October 1st, 2013 without language restrictions. Meta-analysis was conducted using the STATA 12.0 software. Crude odds ratios (ORs) or standardized mean difference (SMD) with their 95% confidence intervals (95% CIs) were calculated. Twelve case–control studies that met all the inclusion criteria were included in this meta-analysis. A total of 1272 patients with cerebral infarction and 1210 healthy control subjects were involved in this meta-analysis. Our meta-analysis results reveal that the MCP-1 −2518A>G polymorphism might increase the risk of cerebral infarction (A allele vs. G allele: OR=1.37, 95% CI: 1.18–1.60, p<0.001; GA+AA vs. GG: OR=1.33, 95% CI: 1.09–1.62, p=0.005; respectively). Furthermore, cerebral infarction patients had higher levels of serum MCP-1 than did healthy control subjects (SMD=2.96, 95% CI: 2.00–3.92, p<0.001). Statistical analysis revealed no evidence of publication bias in this meta-analysis (all p>0.05). Our findings indicate that the MCP-1 −2518A>G polymorphism and serum MCP-1 levels may contribute to the development of cerebral infarction. Thus, the MCP-1 −2518A>G polymorphism and serum MCP-1 levels could be potential biomarkers for the early detection of cerebral infarction.
Get full access to this article
View all access options for this article.
References
1.
ArakelyanA., PetrkovaJ., HermanovaZ., BoyajyanA., LuklJ., and PetrekM. (2005). Serum levels of the MCP-1 chemokine in patients with ischemic stroke and myocardial infarction. Mediators Inflamm, 2005, 175–179.
2.
BoseS., and ChoJ. (2013). Role of chemokine CCL2 and its receptor CCR2 in neurodegenerative diseases. Arch Pharm Res, 36, 1039–1050.
3.
BuraczynskaK., LuchowskiP., WojczalJ., KsiazekA., and StelmasiakZ. (2010). Monocyte chemoattractant protein (MCP-1) A-2518G gene polymorphism in stroke patients with different comorbidities. Clin Biochem, 43, 1421–1426.
4.
ChenS.Y., ZhangZ.J., WuX.L., WangZ.Q., WangW., and YangQ.D. (2007). Study the relationship between the monocyte chemoattractant protein-1 gene-2518G/A polymorphism and cerebral infarction of Han population in Chinese Hunan district. J Clin Neurol, 3, 167–169.
5.
DaiY.M., GuanG.Y., HanH., ZhaoQ.J., SuZ.Q., and ZhangL.M. (2006). Analysis of the MCP-1 promoter-2518A/G gene polymorphism in cerebral infarction patients. J Apoplexy Nerv Dis, 2, 152–154.
6.
DenesA., ThorntonP., RothwellN.J., and AllanS.M. (2010). Inflammation and brain injury: acute cerebral ischaemia, peripheral and central inflammation. Brain Behav Immun, 24, 708–723.
7.
DeshmaneS.L., KremlevS., AminiS., and SawayaB.E. (2009). Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res, 29, 313–326.
8.
FlexA., GaetaniE., PapaleoP., StrafaceG., ProiaA.S., PecoriniG., TondiP., PolaP., et al. (2004). Proinflammatory genetic profiles in subjects with history of ischemic stroke. Stroke, 35, 2270–2275.
9.
GiannakopoulouE., RagiaG., MarousiS., EllulJ., ManolopoulosV.G., and TavridouA. (2013). Association of monocyte chemoattractant protein-1-2518A>G polymorphism with occurrence, severity, and outcome in ischemic stroke. Neurol Sci, 34, 1315–1320.
10.
GuoX.F., LiY.G., LiH.Y., and XiaY.K. (2008). Changes of serum MCP-1 and TF in patients with acute cerebral infarction. Chin J Geriatric Heart Brain Vessel Dis, 10, 790.
11.
HuangJ.M., JiangC.D., TangX.L., MengL.Q., LiX.B., and HuangR.Y. (2011). Changes of serum NF-κb MCP-1 in eldly patients with infarction with carotid artery stenosis. Basic Clin Med, 21, 1394–1395.
12.
JaipersadA.S., LipG.Y., SilvermanS., and ShantsilaE. (2013). The role of monocytes in angiogenesis and atherosclerosis. J Am Coll Cardiol, 63, 1–11.
13.
JeonH.J., ChoiH.J., ParkB.H., LeeY.H., and OhT. (2013). Association of monocyte chemoattractant protein-1 (MCP-1) 2518A/G polymorphism with proliferative diabetic retinopathy in Korean type 2 diabetes. Yonsei Med J, 54, 621–625.
14.
JinR., YangG., and LiG. (2010). Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. J Leukoc Biol, 87, 779–789.
15.
KimS.H., LeeJ.W., ImJ.A., and HwangH.J. (2011). Monocyte chemoattractant protein-1 is related to metabolic syndrome and homocysteine in subjects without clinically significant atherosclerotic cardiovascular disease. Scand J Clin Lab Invest, 71, 1–6.
16.
LekerR.R. (2009). Fate and manipulations of endogenous neural stem cells following brain ischemia. Expert Opin Biol Ther, 9, 1117–1125.
17.
LiangH.F., WangH., ZhangY.X., ZhangH.L., and YuJ. (2011). Study on relationship between monocyte chemoattractant protein-1 gene −2518G/A polymorphism and cerebral infarction of Hasake population in Chinese Xinjiang district. Clin Focus, 26, 2025–2028.
18.
LosyJ., and ZarembaJ. (2001). Monocyte chemoattractant protein-1 is increased in the cerebrospinal fluid of patients with ischemic stroke. Stroke, 32, 2695–2696.
19.
MaoB., ZhangJ., and ZhuoF. (2013). MCP-1-2518A>G polymorphism and myocardial infarction risk: a meta-analysis and meta-regression. Genet Test Mol Biomarkers, 17, 857–863.
20.
MatosM.F., LourencoD.M., OrikazaC.M., BajerlJ.A., NogutiM.A., and MorelliV.M. (2011). The role of IL-6, IL-8 and MCP-1 and their promoter polymorphisms IL-6-174GC, IL-8-251AT and MCP-1-2518AG in the risk of venous thromboembolism: a case-control study. Thromb Res, 128, 216–220.
21.
McCollB.W., AllanS.M., and RothwellN.J. (2009). Systemic infection, inflammation and acute ischemic stroke. Neuroscience, 158, 1049–1061.
22.
O'DonnellM.J., XavierD., LiuL., ZhangH., ChinS.L., Rao-MelaciniP., RangarajanS., IslamS., et al. (2010). Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet, 376, 112–123.
23.
OpdenakkerG., FitenP., NysG., FroyenG., Van RoyN., SpelemanF., LaureysG., and Van DammeJ. (1994). The human MCP-3 gene (SCYA7): cloning, sequence analysis, and assignment to the C-C chemokine gene cluster on chromosome 17q11.2-q12. Genomics, 21, 403–408.
24.
PaneeJ. (2012). Monocyte chemoattractant protein 1 (MCP-1) in obesity and diabetes. Cytokine, 60, 1–12.
25.
ParissisJ.T., AdamopoulosS., VenetsanouK.F., MentzikofD.G., KarasS.M., and KremastinosD.T. (2002). Serum profiles of C-C chemokines in acute myocardial infarction: possible implication in postinfarction left ventricular remodeling. J Interferon Cytokine Res, 22, 223–229.
26.
PetersJ.L., SuttonA.J., JonesD.R., AbramsK.R., and RushtonL. (2006). Comparison of two methods to detect publication bias in meta-analysis. JAMA, 295, 676–680.
27.
PiemontiL., CaloriG., LattuadaG., MercalliA., RagognaF., GaranciniM.P., RuotoloG., LuziL., et al. (2009). Association between plasma monocyte chemoattractant protein-1 concentration and cardiovascular disease mortality in middle-aged diabetic and nondiabetic individuals. Diabetes Care, 32, 2105–2110.
28.
Sanchez-MorenoC., DasheJ.F., ScottT., ThalerD., FolsteinM.F., and MartinA. (2004). Decreased levels of plasma vitamin C and increased concentrations of inflammatory and oxidative stress markers after stroke. Stroke, 35, 163–168.
29.
SenS., RabinsteinA.A., ElkindM.S., and PowersW.J. (2012). Recent developments regarding human immunodeficiency virus infection and stroke. Cerebrovasc Dis, 33, 209–218.
30.
ShimizuM., YoshimuraS., TakizawaS., KoharaS., InokoH., and TakagiS. (2013). Effect of single nucleotide polymorphisms of the prostacyclin receptor gene on platelet activation in Japanese healthy subjects and patients with cerebral infarction. J Clin Neurosci, 20, 851–856.
31.
StangA. (2010). Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol, 25, 603–605.
32.
TowfighiA., and SaverJ.L. (2011). Stroke declines from third to fourth leading cause of death in the United States: historical perspective and challenges ahead. Stroke, 42, 2351–2355.
33.
UchidaE., AnanF., MasakiT., KanedaK., NawataT., EshimaN., SaikawaT., and YoshimatsuH. (2012). Monocyte chemoattractant protein-1 is associated with silent cerebral infarction in patients on haemodialysis. Intern Med J, 42, 29–34.
34.
WangL., MeiY.W., SunZ.T., SongL.Y., ShiN., and LiG.L. (2009). Changes of serum MCP-1 in patients with acute cerebral infarction and intervention effect of atorvastatin. J Shanxi Med Univ, 40, 344–346.
35.
WangX.X., and ChengG.P. (2009). The clinical significance of changes of serum TNF-α, VCAM-1 and MCP-1 in patients with acute cerebral infarction. Prevent Treatm Cardio Cerebral Vascular Dis, 9, 359–360.
36.
XuY.Y., YuanQ., and LiS.Y. (2011). Relationship between MCP-1and VE-cadherin and acute cerebral infarction with before cycle and carotid atherosclerosis. J Apoplexy Nervous Dis, 28, 1019–1021.
37.
YadavA., SainiV., and AroraS. (2010). MCP-1: chemoattractant with a role beyond immunity: a review. Clin Chim Acta, 411, 1570–1579.
38.
YanY.P., SailorK.A., LangB.T., ParkS.W., VemugantiR., and DempseyR.J. (2007). Monocyte chemoattractant protein-1 plays a critical role in neuroblast migration after focal cerebral ischemia. J Cereb Blood Flow Metab, 27, 1213–1224.
39.
YuasaS., MaruyamaT., YamamotoY., HiroseH., KawaiT., Matsunaga-IrieS., and ItohH. (2009). MCP-1 gene A-2518G polymorphism and carotid artery atherosclerosis in patients with type 2 diabetes. Diabetes Res Clin Pract, 86, 193–198.
40.
ZarembaJ., IlkowskiJ., and LosyJ. (2006). Serial measurements of levels of the chemokines CCL2, CCL3 and CCL5 in serum of patients with acute ischaemic stroke. Folia Neuropathol, 44, 282–289.
41.
ZintzarasE., and IoannidisJ.P. (2005). HEGESMA: genome search meta-analysis and heterogeneity testing. Bioinformatics, 21, 3672–3673.
